Drug Type Small molecule drug |
Synonyms TAK 901 |
Target |
Action inhibitors, antagonists |
Mechanism Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), EphA2 antagonists(Ephrin type-A receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC28H32N4O3S |
InChIKeyWKDACQVEJIVHMZ-UHFFFAOYSA-N |
CAS Registry934541-31-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Oct 2009 | |
| Acute Lymphoblastic Leukemia | Phase 1 | United States | 01 Mar 2009 | |
| Acute Myeloid Leukemia | Phase 1 | United States | 01 Mar 2009 | |
| Chronic Lymphocytic Leukemia | Phase 1 | United States | 01 Mar 2009 | |
| Multiple Myeloma | Phase 1 | United States | 01 Mar 2009 | |
| Myelodysplastic Syndromes | Phase 1 | United States | 01 Mar 2009 | |
| Myelofibrosis | Phase 1 | United States | 01 Mar 2009 | |
| Philadelphia chromosome positive chronic myelogenous leukemia | Phase 1 | United States | 01 Mar 2009 | |
| Polycythemia | Phase 1 | United States | 01 Mar 2009 | |
| Primary Myelofibrosis | Phase 1 | United States | 01 Mar 2009 |





